NEW YORK, March 21, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Pfizer Inc. Analyst Notes
On March 18, 2014, Pfizer Inc. (Pfizer) announced the launch of its fourth integrated annual review, which summarizes its 2013 financial, environmental, and social responsibility performance. The Company first combined the reporting of corporate responsibility activities, financial performance, and business strategy with its 2010 annual review and since then has continued to advance the integrated reporting of information relevant to all of the Pfizer's stakeholders. Summarizing the Company's financial performance, Chairman and CEO Ian C. Read stated, "In 2013, Pfizer achieved solid results for patients, consumers, and shareholders by maintaining our focus on developing new therapies, driving growth, and delivering value. Health care providers, regulators, and patients look to Pfizer to deliver medicines and vaccines that make peoples' lives better. By earning their trust, we also earn greater respect from society." The full analyst notes on Pfizer Inc. are available to download free of charge at:
Magellan Health Services Inc. Analyst Notes
On March 14, 2014, Magellan Health Services Inc. (Magellan Health Services) announced that it will release its Q1 2014 earnings results on April 29, 2014 at approximately 6:30 a.m. ET. According to the Company, Magellan Health Services' management will discuss the financial results along with its business strategy and outlook in a conference call that will be held on the same day from 11:00 a.m. to 12:00 noon ET. The full analyst notes on Magellan Health Services Inc. are available to download free of charge at:
Prothena Corporation plc Analyst Notes
On March 18, 2014, Prothena Corporation plc (Prothena) announced that an abstract (Abstract #PB-48) reviewing interim clinical data from its ongoing Phase 1 study of NEOD001 (a humanized monoclonal antibody) in patients with immunoglobulin light chain (AL) amyloidosis and persistent organ dysfunction will be presented at the XIV International Symposium on Amyloidosis (ISA). According to the Company, the presentation at the ISA in Indianapolis, Indiana, will be made by Dr. Michaela Liedtke from Stanford Cancer Institute, Stanford, California, on April 29, 2014. The full analyst notes on Prothena Corporation plc are available to download free of charge at:
Alere Inc. Analyst Notes
On March 3, 2014, Alere Inc. (Alere) declared a cash dividend of $3.00 per share on the Company's Series B Convertible Perpetual Preferred Stock. According to the Company, the dividend is payable on April 15, 2014, to shareholders of record of Series B stock at the close of business on April 1, 2014. Such payment will cover the amount of all dividends accrued from January 1, 2014 through March 31, 2014, reported the Company. The full analyst notes on Alere Inc. are available to download free of charge at:
KYTHERA Biopharmaceuticals, Inc. Analyst Notes
On March 10, 2014, KYTHERA Biopharmaceuticals, Inc. (KYTHERA) along with Bayer Consumer Care (Bayer) announced that the Company has acquired all rights to a proprietary formulation of a purified synthetic version of deoxycholic acid currently in late-stage development for the reduction of submental fat (double chin) - ATX-101, outside of the U.S. and Canada. As per the agreement, the rights have been acquired by KYTHERA Holdings Ltd, a wholly-owned Bermuda subsidiary of the Company to develop and commercialize ATX-101 outside the U.S. and Canada. Additionally, the Company stated that Bayer will receive $33 million in KYTHERA common stock along with a $51 million note payable no later than 2014. Commenting on the acquisition, Keith Leonard, Company President and CEO, stated, "We are very pleased to acquire all rights to ATX-101 outside the U.S. and Canada, giving us full global rights to develop and commercialize ATX-101. I am confident in our ability to maximize the long-term global value of ATX-101. While our primary focus remains filing our U.S. New Drug Application in the second quarter of 2014, we also plan to make multiple ex-U.S. regulatory submissions in the next 12 months." The full analyst notes on KYTHERA Biopharmaceuticals, Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review